Grotta James C, Hacke Werner
From the Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.); and Department of Neurology, University Hospital Heidelberg, Ruprecht-Karls University, Heidelberg, Germany (W.H.).
Stroke. 2015 Jun;46(6):1447-52. doi: 10.1161/STROKEAHA.115.008384. Epub 2015 May 5.
Before December 2014, the only proven effective treatment for acute ischemic stroke was recombinant tissue-type plasminogen activator (r-tPA). This has now changed with the publication of the Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands (MR CLEAN), Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion With Emphasis on Minimizing CT to Recanalization Times (ESCAPE), Extending the Time for Thrombolysis in Emergency Neurological Deficits--Intra-Arterial (EXTEND IA), Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment Trial (SWIFT PRIME), and Randomized Trial of Revascularization With the Solitaire FR Device Versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting Within Eight Hours of Symptom Onset (REVASCAT) studies. We review the main results of these studies and how they inform stroke patient management going forward. The main take home points for neurologists are (1) intra-arterial thrombectomy is a potently effective treatment and should be offered to patients who have documented occlusion in the distal internal carotid or the proximal middle cerebral artery, have a relatively normal noncontrast head computed tomographic scan, severe neurological deficit, and can have intra-arterial thrombectomy within 6 hours of last seen normal; (2) benefits are clear in patients receiving r-tPA before intra-arterial thrombectomy; r-tPA should not be withheld if the patient meets criteria, and benefit in patients who do not receive r-tPA or have r-tPA exclusions requires further study; and (3) these favorable results occur when intra-arterial thrombectomy is performed in an endovascular stroke center by a coordinated multidisciplinary team that extends from the prehospital stage to the endovascular suite, minimizes time to recanalization, uses stent-retriever devices, and avoids general anesthesia. In conclusion, stroke teams, including practicing neurologists caring for patients with stroke should now provide the option for intra-arterial thrombectomy for a subset of patients with acute stroke.
2014年12月之前,急性缺血性卒中唯一经证实有效的治疗方法是重组组织型纤溶酶原激活剂(r-tPA)。随着荷兰急性缺血性卒中血管内治疗多中心随机临床试验(MR CLEAN)、以最小化CT至再通时间为重点的小核心和前循环近端闭塞血管内治疗(ESCAPE)、延长紧急神经功能缺损溶栓时间——动脉内治疗(EXTEND IA)、以血栓切除术为主要血管内治疗手段的Solitaire试验(SWIFT PRIME)以及在症状发作8小时内出现的前循环大血管闭塞所致急性卒中治疗中使用Solitaire FR装置血管再通与最佳药物治疗随机试验(REVASCAT)等研究的发表,这种情况现已改变。我们回顾这些研究的主要结果以及它们对未来卒中患者管理的指导作用。神经科医生的主要收获是:(1)动脉内血栓切除术是一种非常有效的治疗方法,应提供给已记录有颈内动脉远端或大脑中动脉近端闭塞、非增强头部计算机断层扫描相对正常、有严重神经功能缺损且能在最后一次正常状态后6小时内接受动脉内血栓切除术的患者;(2)在动脉内血栓切除术之前接受r-tPA治疗的患者,其获益是明确的;如果患者符合标准,不应停用r-tPA,对于未接受r-tPA或被排除使用r-tPA的患者的获益需要进一步研究;(3)当由一个从院前阶段到血管内手术室的协调多学科团队在血管内卒中中心进行动脉内血栓切除术时,能实现这些良好结果,该团队可将再通时间降至最短,使用支架取栓装置,并避免全身麻醉。总之,包括照顾卒中患者的执业神经科医生在内的卒中团队,现在应为一部分急性卒中患者提供动脉内血栓切除术的选择。